| Literature DB >> 24886840 |
Giovanni Minervini1, Elisabetta Panizzoni1, Manuel Giollo2, Alessandro Masiero1, Carlo Ferrari3, Silvio C E Tosatto1.
Abstract
Von Hippel-Lindau (VHL) syndrome is a hereditary condition predisposing to the development of different cancer forms, related to germline inactivation of the homonymous tumor suppressor pVHL. The best characterized function of pVHL is the ubiquitination dependent degradation of Hypoxia Inducible Factor (HIF) via the proteasome. It is also involved in several cellular pathways acting as a molecular hub and interacting with more than 200 different proteins. Molecular details of pVHL plasticity remain in large part unknown. Here, we present a novel manually curated Petri Net (PN) model of the main pVHL functional pathways. The model was built using functional information derived from the literature. It includes all major pVHL functions and is able to credibly reproduce VHL syndrome at the molecular level. The reliability of the PN model also allowed in silico knockout experiments, driven by previous model analysis. Interestingly, PN analysis suggests that the variability of different VHL manifestations is correlated with the concomitant inactivation of different metabolic pathways.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24886840 PMCID: PMC4041725 DOI: 10.1371/journal.pone.0096986
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Top level model.
The colors of some tokens were arbitrarily chosen to give a clearer identification of the central nodes (ATP, Vcb and oxygen) or for nodes involved in more reactions such as GSK3β. The group of nodes in the bottom left is not disconnected from the central body of the network thanks to the presence of logic nodes for ATP synthesis (t_97).
Figure 3Lower hierarchical PN levels, in particular HIF-1α regulation and HIF-1α-dependent pro-angiogenic signaling.
VEGF and EPO pathways are at a lower hierarchical level than the pro_angio macro-node.
Figure 2Lower hierarchical PN levels.
Pathways from the top level are grouped in macro-nodes (functional subordinated layer), in particular glucidic metabolism and various VHL functions.
Figure 4PinA Distance Matrix clustering, using Tanimoto coefficient and 65% threshold of.
The numbers indicates clusters. In C8, C9, C10, C11 are highlighted a red square.
List of Trivial T-invariants excluded from calculation with their associated biological meaning.
| Trivial T-Invariants | ID transitions | Biological Meaning |
| TInv_1 | t_99, t_100 | Glycongen Synthase regulation |
| TInv_2 | t_101, t_102 | Pkb regulation |
| TInv_3 | t_103, t_132 | GSK3β active-inactive state |
| TInv_4 | t_174, t_222 | Par6 inactivation via aPKCζ2 |
| TInv_5 | t_177, t_208 | VHL binding to Sp1 |
| TInv_6 | t_167, t_199 | Sp1 phosphorylation and dephosphorylation |
| TInv_7 | t_0, t_2 | Hif transport in and out of nucleus |
| TInv_8 | t_0, t_234 | Hif inhibition via FIH |
| TInv_9 | t_181, t_207 | Hur inhibition via VHL |
| TInv_10 | t_231, t_232 | IGFR mRNA production and destruction |
List of MCTS and transitions from PInA.
| MCTS | ID Transitions |
| MCTS 1 (M1) | t_0, t_190, t_191, t_192; |
| MCTS 2 (M2) | t_1, t_3, t_4, t_5, t_6, t_7, t_8, t_9, t_10, t_11, t_12, t_32, t_51, t_52, t_53, t_54, t_55, t_56, t_57, t_58, t_59, t_60, t_61, t_62, t_63, t_64, t_65, t_66, t_67, t_79, t_83, t_123, t_129, t_138, t_215; |
| MCTS 3 (M3) | t_2, t_99, t_100, t_101, t_102, t_103, t_132, t_167, t_174, t_181, t_199,_177, t_207, t_208, t_222, t_232, t_234; |
| MCTS 4 (M4) | t_13, t_16, t_17, t_18, t_19, t_20, t_124, t_128; |
| MCTS 5 (M5) | t_14, t_21, t_23, t_24, t_25, t_26, t_27, t_31, t_126; |
| MCTS 6 (M6) | t_15, t_22, t_28, t_29, t_30, t_125, t_142; |
| MCTS 7 (M7) | t_33, t_34; |
| MCTS 8 (M8) | t_35, t_36; |
| MCTS 9 (M9) | t_37, t_130; |
| MCTS 10 (M10) | t_38, t_39, t_40, t_41, t_42, t_43, t_44, t_45, t_46, t_47, t_48, t_49, t_50, t_127; |
| MCTS 11 (M11) | t_68, t_70, t_71, t_72, t_73, t_74, t_75, t_76, t_77, t_78, t_237; |
| MCTS 12 (M12) | t_80, t_111, t_112; |
| MCTS 13 (M13) | t_81, t_84, t_85, t_86, t_87, t_88, t_89, t_90, t_131; |
| MCTS 14 (M14) | t_92, t_93; |
| MCTS 15 (M15) | t_95, t_104, t_141; |
| MCTS 16 (M16) | t_96, t_105, t_218; |
| MCTS 17 (M17) | t_97, t_224; |
| MCTS 18 (M18) | t_106, t_107, t_108; |
| MCTS 19 (M19) | t_109, t_110, t_133; |
| MCTS 20 (M20) | t_113, t_115, t_117, t_118, t_119; |
| MCTS 21 (M21) | t_134, t_135, t_136, t_137; |
| MCTS 22 (M22) | t_139, t_140, t_217; |
| MCTS 23 (M23) | t_143, t_227, t_228; |
| MCTS 24 (M24) | t_144, t_145, t_146; |
| MCTS 25 (M25) | t_147, t_148, t_149; |
| MCTS 26 (M26) | t_150, t_151, t_219; |
| MCTS 27 (M27) | t_152, t_153, t_154, t_220; |
| MCTS 28 (M28) | t_155, t_156, t_157, t_158, t_159, t_160, t_221, t_226; |
| MCTS 29 (M29) | t_161, t_163, t_164, t_166, t_213; |
| MCTS 30 (M30) | t_162, t_165, t_214; |
| MCTS 31 (M31) | t_168, t_169, t_201, t_236; |
| MCTS 32 (M32) | t_170, t_171, t_172, t_173, t_223; |
| MCTS 33 (M33) | t_175, t_176, t_180, t_230; |
| MCTS 34 (M34) | t_178, t_203; |
| MCTS 35 (M35) | t_182, t_183, t_231, t_233; |
| MCTS 36 (M36) | t_184, t_185, t_186, t_187, t_188, t_189, t_198; |
| MCTS 37 (M37) | t_193, t_194; |
| MCTS 38 (M38) | t_195, t_196, t_197, t_200; |
| MCTS 39 (M39) | t_204, t_205, t_206, t_235; |
| MCTS 40 (M40) | t_210, t_211; |
Figure 5Transitions occurrence T-invariants.
Transitions are ordered by name and t_98 is highlighted in red.
Ranking of the 10 most occurring transitions with biological meaning and percentage of occurrence.
| Rank | Transitions | Biological meaning | Occurrence % |
| 1 | t_98 | Input transition for Hif and VHL | 95.165 |
| 2 | t_116 | Interaction of VHL with Elongin B and C | 94.148 |
| 3 | t_113 | Activation by oxygen of ARD | 94.094 |
| 4 | t_115 | Acetylation and hydroxilation of Hif | 94.094 |
| 5 | t_117 | Interaction of complex Vcb with Cu2 | 94.094 |
| 6 | t_118 | Interaction of complex Vcb with modified Hif | 94.094 |
| 7 | t_119 | Degradation VHL dependent of Hif | 94.094 |
| 8 | t_97 | ATP formation | 89.059 |
| 9 | t_224 | Water Output transition | 89.059 |
| 10 | t_82 | Pyruvate Dehydrogenase inactivation | 88.041 |